Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today published data from a clinical
study that stratifies colon cancer patients into groups of high, medium and low
chances of survival which may prove useful for optimizing the treatment of each
individual cancer patient.

Exiqon has analyzed 130 stage II colon cancer patients for the expression of
microRNA-21 in the tumor tissue. The study was based on in situ hybridization
enabled by Exiqon's proprietary LNA™ detection technology.

The study demonstrated that among the 33% of the patients with the highest
microRNA-21 levels, only 73% survived two years after surgery, whereas the same
rate was 98% among the 33% of the patients with the lowest microRNA-21 levels.
For the medium group, 86% survived two years after surgery.

Data from the study suggests that it may be possible to clinically stratify
colon cancer patients. This would potentially allow for optimization of the
individual patient's treatment on the basis of an analysis of each patient's
risk profile. Oncologist may want to offer adjuvant chemotherapy after surgery
to high-risk group of patients in stage II which may today not be treated with
adjuvant chemotherapy irrespective of recurrence rates of up to 25% of this
patient population. Today, patients diagnosed with colon cancer stage III are
already commonly offered adjuvant chemotherapy treatment after surgery.

Annually, colon cancer affects about 108,000 people in the U.S. with 25% of
them diagnosed as stage II. Colon cancer is currently the third leading cause
of cancer death in the U.S. In Denmark alone, approximately 2,450 patients are
diagnosed with colon cancer annually, and approximately 900 of these are
diagnosed stage II patients.

On the basis of the study results, Exiqon is planning to conduct additional
validation studies and conclude a partnership agreement with a diagnostic or
pharmaceutical company on the final development and marketing of a (companion)
diagnostic kit for stratification of stage II colon cancer patients potentially
eligible for adjuvant chemotherapy.

Exiqon already markets research reagents and kits that support this type of
analyses.

The paper is freely available at:
http://www.springerlink.com/content/b18587r00882m050/

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full release in the attached PDF or at www.exiqon.com/investor/portal

announcement_20_2010_recurrence.pdf